Navigation Links
Syngenta Ventures Invests in U.S. Biotech Company Metabolon
Date:10/27/2009

BASEL, Switzerland, Oct. 27 /PRNewswire-FirstCall/ -- Syngenta Ventures announced today that it has made an equity investment in Metabolon, a privately-held U.S. biotechnology company focused on the use of metabolomics in research and diagnostics. This is the first direct investment by Syngenta Ventures, Syngenta's newly-established corporate venture capital subsidiary.

"The creation of Syngenta Ventures will complement our in-house R&D work and enables us to be even more involved in promising technologies and innovative products with external partners," said Robert Berendes, Head of Business Development at Syngenta. "We need access to the best available new technologies in order to achieve the increase in agricultural output which will be vital over the coming years."

Sandro Aruffo, Head of Research and Development at Syngenta, added: "This investment follows a research collaboration with Metabolon which has existed for some years. We believe Metabolon's unique metabolomics platform will be an increasingly important technology for the development of innovative new products in the agriculture industry."

Metabolomics provides mechanistic insight and biochemical markers for complex biological processes. This technology aims to accelerate the development of plants with innovative new native and genetically modified traits.

Syngenta Ventures will take a seat on the Board of Metabolon. The equity investment was made in the Series C financing of Metabolon which raised in total $12.3 million from a number of investors, including Syngenta Ventures. Financial details of the equity investment were not disclosed.

About Syngenta

Syngenta (NYSE: SYT) is one of the world's leading companies with more than 24,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

About Metabolon

Metabolon is a diagnostics and services company offering the industry's leading biochemical profiling platform. Metabolon's patented platform provides a global analysis of complex biological samples for the discovery of markers. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.

    Media contacts:

    Medard Schoenmaeckers
    Switzerland       +41 61 323 2323

    Paul Minehart
    USA               +1 202 737 8913

    Analyst/Investor contacts:

    Jennifer Gough
    Switzerland       +41 61 323 5059
    USA               +1 202 737 6521

    John Hudson
    Switzerland       +41 61 323 6793
    USA               +1 202 737 6520

SOURCE Syngenta


'/>"/>
SOURCE Syngenta
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta Licenses Chromatin Gene Stacking Technology
2. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
3. Syngenta To Build Major Global Biotech Research Center in Beijing, China
4. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
5. Syngenta and Metabolon Inc. in Collaborative Research Agreement for Biochemical Profiling Technology
6. Syngenta Enters Into Research Collaboration With Anhui Academy, China
7. Syngenta Board Proposes Stefan Borgas to Become New Director
8. Syngenta holds Annual General Meeting
9. Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields
10. Syngenta Issues EUR 500 Million Eurobond
11. Syngenta and Evogene to Collaborate on Soybean Nematode Resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... FDA’s GMP expectations for phase I clinical trials comes to Tampa, San Francisco ... biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., Teva ...
(Date:4/26/2017)... ... April 26, 2017 , ... As the call for prior ... stakeholders, the discussion surrounding the topic will continue at WEDI 2017- Driving Solutions ... Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), the nation’s ...
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... of L3 Healthcare, is pleased to announce the company is now a certified ... The iMedNet software certification enables the company’s clinical research team to build, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review ... be featured in multiple sessions at this week’s Association of Clinical Research Professionals ... best practices in clinical research. , "We are excited to present subject matter expertise ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):